{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T22:56:49Z","timestamp":1756076209906,"version":"3.33.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Supplement 3","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2011,10,26]],"date-time":"2011-10-26T00:00:00Z","timestamp":1319587200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,11]]},"abstract":"<jats:sec>\n            <jats:title>Key Points<\/jats:title>\n            <jats:p>1. Renal function is frequently compromised in candidates for transplantation with advanced cirrhosis. These patients frequently have chronic and irreversible kidney changes at the time of transplantation.<\/jats:p>\n            <jats:p>2. The accumulated incidence of chronic renal failure is high in liver transplant recipients. Chronic renal failure has a deleterious impact on the outcome.<\/jats:p>\n            <jats:p>3. Calcineurin inhibitor (CNI)\u2013based immunosuppression is highly effective at preventing rejection. However, CNI nephrotoxicity has a central role in the occurrence of chronic renal failure.<\/jats:p>\n            <jats:p>4. Renal function impairment frequently occurs within the first year after transplantation. Once renal function is significantly impaired [glomerular filtration rate (GFR) &lt; 60 mL\/minute\/1.73 m<jats:sup>2<\/jats:sup>], any intervention is unlikely to result in a return to normal renal function. Early interventions are needed to prevent chronic and irreversible kidney injury.<\/jats:p>\n            <jats:p>5. De novo CNI minimization has been proven to be effective at reducing the rate of impaired renal function after transplantation. The reduction in the CNI doses should be offset by the addition of mycophenolate mofetil or enteric-coated mycophenolate sodium.<\/jats:p>\n            <jats:p>6. Delayed CNI minimization in patients with established renal insufficiency may result in a significant improvement in the GFR, even though the increase in the GFR after minimization is generally modest.<\/jats:p>\n            <jats:p>7. Mammalian target of rapamycin (mTOR) inhibitors are considered nonnephrotoxic immunosuppressive agents. They may be an option for improving renal function in liver transplant recipients. However, not all patients with renal dysfunction benefit from a switch to mTOR inhibitors. In addition, the benefits in terms of renal function should be balanced against specific side effects.<\/jats:p>\n            <jats:p>8. New immunosuppressive agents without intrinsic nephrotoxicity are currently under development for solid organ transplantation. These agents could help to reduce the burden of impaired renal function in transplantation in the near future.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/lt.22392","type":"journal-article","created":{"date-parts":[[2011,7,27]],"date-time":"2011-07-27T14:34:41Z","timestamp":1311777281000},"page":"S43-S49","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Hot-topic debate on kidney function: Renal-sparing approaches are beneficial"],"prefix":"10.1097","volume":"17","author":[{"given":"Fran\u00e7ois","family":"Durand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-9-20250124","doi-asserted-by":"crossref","first-page":"11691177","DOI":"10.1002\/lt.22128","article-title":"Inaccuracies of creatinine and creatininebased equations in candidates for liver transplantation with low creatinine: impact on the Model for EndStage Liver Disease score.","volume":"16","author":"Francoz","year":"2010","journal-title":"Liver Transpl"},{"key":"R2-9-20250124","doi-asserted-by":"crossref","first-page":"523528","DOI":"10.1016\/j.jhep.2010.01.009","article-title":"Serum sodium, renal function, and survival of patients with endstage liver disease.","volume":"52","author":"Lim","year":"2010","journal-title":"J Hepatol"},{"key":"R3-9-20250124","doi-asserted-by":"crossref","first-page":"754761","DOI":"10.1002\/lt.20686","article-title":"Impact of implementation of the MELD scoring system on the prevalence and incidence of chronic renal disease following liver transplantation.","volume":"12","author":"Machicao","year":"2006","journal-title":"Liver Transpl"},{"key":"R4-9-20250124","doi-asserted-by":"crossref","first-page":"233243","DOI":"10.1053\/jhep.2003.50084","article-title":"Acute renal failure in patients with cirrhosis: perspectives in the age of MELD.","volume":"37","author":"Moreau","year":"2003","journal-title":"Hepatology"},{"key":"R5-9-20250124","doi-asserted-by":"crossref","first-page":"838843","DOI":"10.1002\/lt.21149","article-title":"Hepatorenal syndrome: a proposal for kidney after liver transplantation (KALT).","volume":"13","author":"Ruiz","year":"2007","journal-title":"Liver Transpl"},{"key":"R6-9-20250124","doi-asserted-by":"crossref","first-page":"478482","DOI":"10.1093\/ndt\/gfi212","article-title":"The course of type 1 hepatorenal syndrome post liver transplantation.","volume":"21","author":"Marik","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"R7-9-20250124","doi-asserted-by":"crossref","first-page":"725732","DOI":"10.1111\/j.1478-3231.2009.02182.x","article-title":"The spectrum of renal lesions in patients with cirrhosis: a clinicopathological study.","volume":"30","author":"Trawale","year":"2010","journal-title":"Liver Int"},{"key":"R8-9-20250124","doi-asserted-by":"crossref","first-page":"931940","DOI":"10.1056\/NEJMoa021744","article-title":"Chronic renal failure after transplantation of a nonrenal organ.","volume":"349","author":"Ojo","year":"2003","journal-title":"N Engl J Med"},{"key":"R9-9-20250124","doi-asserted-by":"crossref","first-page":"26512659","DOI":"10.1111\/j.1600-6143.2006.01526.x","article-title":"Continued influence of preoperative renal function on outcome of orthotopic liver transplant (OLTX) in the US: where will MELD lead us?","volume":"6","author":"Gonwa","year":"2006","journal-title":"Am J Transplant"},{"key":"R10-9-20250124","first-page":"26302636","article-title":"Chronic kidney disease postliver transplantation.","volume":"21","author":"ORiordan","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"R11-9-20250124","doi-asserted-by":"crossref","first-page":"11201129","DOI":"10.1111\/j.1600-6143.2005.00852.x","article-title":"Renal histopathological lesions after orthotopic liver transplantation (OLT).","volume":"5","author":"Pillebout","year":"2005","journal-title":"Am J Transplant"},{"key":"R12-9-20250124","doi-asserted-by":"crossref","first-page":"10411054","DOI":"10.1016\/j.jhep.2010.12.001","article-title":"Immunosuppression in liver transplant recipients with renal impairment.","volume":"54","author":"Duvoux","year":"2011","journal-title":"J Hepatol"},{"key":"R13-9-20250124","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1016\/j.phrs.2011.03.013","article-title":"Challenges in diagnosing acute calcineurininhibitor induced nephrotoxicity: from toxicogenomics to emerging biomarkers.","volume":"64","author":"Pallet","year":"2011","journal-title":"Pharmacol Res"},{"key":"R14-9-20250124","doi-asserted-by":"crossref","first-page":"463468","DOI":"10.1097\/01.tp.0000185305.63759.d3","article-title":"ACE gene DD genotype as a risk factor for chronic nephrotoxicity from calcineurin inhibitors in liver transplant recipients.","volume":"81","author":"Gallon","year":"2006","journal-title":"Transplantation"},{"issue":"suppl 1","key":"R15-9-20250124","first-page":"S1S266","article-title":"KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.","volume":"39","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"R16-9-20250124","doi-asserted-by":"crossref","first-page":"10641072","DOI":"10.1002\/lt.20490","article-title":"Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, lowdose tacrolimus regimen vs. a standarddose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial.","volume":"11","author":"Yoshida","year":"2005","journal-title":"Liver Transpl"},{"key":"R17-9-20250124","doi-asserted-by":"crossref","first-page":"327336","DOI":"10.1111\/j.1600-6143.2008.02493.x","article-title":"; for ReSpECT Study Group. Delayed introduction of reduceddose tacrolimus, and renal function in liver transplantation: the ReSpECT study.","volume":"9","author":"Neuberger","year":"2009","journal-title":"Am J Transplant"},{"key":"R18-9-20250124","doi-asserted-by":"crossref","first-page":"965976","DOI":"10.1111\/j.1600-6143.2011.03486.x","article-title":"Reduceddose tacrolimus with mycophenolate mofetil vs. standarddose tacrolimus in liver transplantation: a randomized study.","volume":"11","author":"Boudjema","year":"2011","journal-title":"Am J Transplant"},{"key":"R19-9-20250124","first-page":"11191125","article-title":"Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial.","volume":"360","author":"OGrady","year":"2002","journal-title":"Lancet"},{"key":"R20-9-20250124","doi-asserted-by":"crossref","first-page":"741747","DOI":"10.1053\/jlts.2003.50113","article-title":"Independent risk factors and natural history of renal dysfunction in liver transplant recipients.","volume":"9","author":"Pawarode","year":"2003","journal-title":"Liver Transpl"},{"key":"R21-9-20250124","doi-asserted-by":"crossref","first-page":"17551760","DOI":"10.1002\/lt.20903","article-title":"Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation.","volume":"12","author":"Pageaux","year":"2006","journal-title":"Liver Transpl"},{"key":"R22-9-20250124","doi-asserted-by":"crossref","first-page":"11951208","DOI":"10.1111\/j.1365-2036.2007.03466.x","article-title":"Clinical trial: switch to combined mycophenolate mofetil and minimal dose calcineurin inhibitor in stable liver transplant patientsassessment of renal and allograft function, cardiovascular risk factors and immune monitoring.","volume":"26","author":"Cicinnati","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"R23-9-20250124","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1097\/01.TP.0000165118.00988.D7","article-title":"Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: randomized, prospective, multicenter pilot study results.","volume":"80","author":"Reich","year":"2005","journal-title":"Transplantation"},{"key":"RU24-9-20250124","doi-asserted-by":"crossref","first-page":"191198","DOI":"10.1111\/j.1399-0012.2009.00965.x","article-title":"Two yr mycophenolate mofetil plus lowdose calcineurin inhibitor for renal dysfunction after liver transplant.","volume":"23","author":"Biselli","year":"2009","journal-title":"Clin Transplant"},{"key":"R25-9-20250124","doi-asserted-by":"crossref","first-page":"587591","DOI":"10.1016\/S0140-6736(00)04055-1","article-title":"Replacement of calcineurin inhibitors with mycophenolate mofetil in livertransplant patients with renal dysfunction: a randomised controlled study.","volume":"357","author":"Schlitt","year":"2001","journal-title":"Lancet"},{"key":"R26-9-20250124","first-page":"610613","article-title":"Mycophenolate mofetil monotherapy for severe side effects of calcineurin inhibitors following liver transplantation.","volume":"9","author":"Dharancy","year":"2009","journal-title":"Am J Transplant"},{"key":"R27-9-20250124","doi-asserted-by":"crossref","first-page":"461468","DOI":"10.1111\/j.1432-2277.2011.01228.x","article-title":"Longterm, maintenance MMF monotherapy improves the fibrosis progression in liver transplant recipients with recurrent hepatitis C.","volume":"24","author":"Manzia","year":"2011","journal-title":"Transpl Int"},{"key":"R28-9-20250124","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1002\/lt.20926","article-title":"Switch to 1.5 grams MMF monotherapy for CNIrelated toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertension.","volume":"13","author":"Orlando","year":"2007","journal-title":"Liver Transpl"},{"key":"R29-9-20250124","first-page":"16501655","article-title":"Mycophenolate mofetil can be used as monotherapy late after liver transplantation.","volume":"4","author":"Moreno Planas","year":"2004","journal-title":"Am J Transplant"},{"key":"R30-9-20250124","doi-asserted-by":"crossref","first-page":"12041211","DOI":"10.1097\/01.tp.0000178393.78084.9b","article-title":"; for the Rapamune Maintenance Regimen Study Group. Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function.","volume":"80","author":"Russ","year":"2005","journal-title":"Transplantation"},{"key":"R31-9-20250124","doi-asserted-by":"crossref","first-page":"651659","DOI":"10.1002\/lt.21429","article-title":"Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over lowdose calcineurin inhibitor regimens.","volume":"14","author":"DuBay","year":"2008","journal-title":"Liver Transpl"},{"key":"R32-9-20250124","doi-asserted-by":"crossref","first-page":"17921797","DOI":"10.1002\/lt.21920","article-title":"Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.","volume":"15","author":"Castroagudin","year":"2009","journal-title":"Liver Transpl"},{"key":"R33-9-20250124","doi-asserted-by":"crossref","first-page":"10591071","DOI":"10.1681\/ASN.V1251059","article-title":"Pharmacokinetic interactions augment toxicities of sirolimuscyclosporine combinations.","volume":"12","author":"Podder","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"R34-9-20250124","doi-asserted-by":"crossref","first-page":"179187","DOI":"10.2174\/157488606776930580","article-title":"Sirolimus early graft nephrotoxicity: clinical and experimental data.","volume":"1","author":"Pallet","year":"2006","journal-title":"Curr Drug Saf"},{"key":"R35-9-20250124","doi-asserted-by":"crossref","first-page":"13591372","DOI":"10.1002\/lt.22193","article-title":"The immunosuppressive pipeline: meeting unmet needs in liver transplantation.","volume":"16","author":"Selzner","year":"2010","journal-title":"Liver Transpl"},{"key":"R36-9-20250124","doi-asserted-by":"crossref","first-page":"535546","DOI":"10.1111\/j.1600-6143.2009.03005.x","article-title":"A phase III study of belataceptbased immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).","volume":"10","author":"Vincenti","year":"2010","journal-title":"Am J Transplant"},{"issue":"suppl 1","key":"R37-9-20250124","first-page":"S79","article-title":"Belataceptbased immunosuppression in de novo liver transplant recipients: 1year experience from a phase II study abstract.","volume":"17","author":"GarciaValdecasas","year":"2011","journal-title":"Liver Transpl"},{"key":"R38-9-20250124","doi-asserted-by":"crossref","first-page":"13231331","DOI":"10.1097\/TP.0b013e3181bd5951","article-title":"Impact of reduced nephron mass on cyclosporine andor sirolimusinduced nephrotoxicity.","volume":"88","author":"Fernandes","year":"2009","journal-title":"Transplantation"}],"container-title":["Liver Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flt.22392","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flt.22392","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01445473-201111003-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T17:09:43Z","timestamp":1737738583000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01445473-201111003-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":38,"journal-issue":{"issue":"Supplement 3","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1002\/lt.22392","relation":{},"ISSN":["1527-6465"],"issn-type":[{"type":"print","value":"1527-6465"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}